Literature DB >> 29483114

Evaluation of the In Vitro Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates.

David R Snydman1, Laura A McDermott2, Nilda V Jacobus2, Kathryn Kerstein3, Trudy H Grossman3, Joyce A Sutcliffe3.   

Abstract

The novel fluorocycline antibiotic eravacycline is in development for use in the treatment of serious infections caused by susceptible and multidrug-resistant (MDR) aerobic and anaerobic Gram-negative and Gram-positive pathogens. Eravacycline and 11 comparator antibiotics were tested against recent anaerobic clinical isolates, including MDR Bacteroides spp. and Clostridium difficile Eravacycline was potent in vitro against all the isolates tested, including strains with tetracycline-specific resistance determinants and MDR anaerobic pathogens resistant to carbapenems and/or β-lactam-β-lactamase inhibitor combinations.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Bacteroides; anaerobes; antimicrobial resistance; eravacycline

Mesh：

Substances：

Year:  2018        PMID： 29483114      PMCID： PMC5923129          DOI： 10.1128/AAC.02206-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.

Authors:  Xiao-Yi Xiao; Diana K Hunt; Jingye Zhou; Roger B Clark; Nick Dunwoody; Corey Fyfe; Trudy H Grossman; William J O'Brien; Louis Plamondon; Magnus Rönn; Cuixiang Sun; Wu-Yan Zhang; Joyce A Sutcliffe
Journal:  J Med Chem       Date:  2012-01-04       Impact factor: 7.446

2.  TetX is a flavin-dependent monooxygenase conferring resistance to tetracycline antibiotics.

Authors:  Wangrong Yang; Ian F Moore; Kalinka P Koteva; David C Bareich; Donald W Hughes; Gerard D Wright
Journal:  J Biol Chem       Date:  2004-09-27       Impact factor: 5.157

3.  In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline.

Authors:  Yunliang Zhang; Xiaoyan Lin; Karen Bush
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

4.  Investigation of the prevalence of tetQ, tetX and tetX1 genes in Bacteroides strains with elevated tigecycline minimum inhibitory concentrations.

Authors:  Noémi Anikó Bartha; József Sóki; Edit Urbán; Elisabeth Nagy
Journal:  Int J Antimicrob Agents       Date:  2011-10-19       Impact factor: 5.283

5.  Eravacycline Is Active against Bacterial Isolates Expressing the Polymyxin Resistance Gene mcr-1.

Authors:  Corey Fyfe; Gabrielle LeBlanc; Brianna Close; Patrice Nordmann; Jacques Dumas; Trudy H Grossman
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

6.  Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City.

Authors:  Marie Abdallah; Olawole Olafisoye; Christopher Cortes; Carl Urban; David Landman; John Quale
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

7.  Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic.

Authors:  Trudy H Grossman; Agata L Starosta; Corey Fyfe; William O'Brien; David M Rothstein; Aleksandra Mikolajka; Daniel N Wilson; Joyce A Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

8.  Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007).

Authors:  David R Snydman; Nilda V Jacobus; Laura A McDermott; Yoav Golan; David W Hecht; Ellie J C Goldstein; Lizzie Harrell; Stephen Jenkins; Duane Newton; Carl Pierson; John D Rihs; Victor L Yu; Richard Venezia; Sydney M Finegold; Jon E Rosenblatt; Sherwood L Gorbach
Journal:  Clin Infect Dis       Date:  2010-01-01       Impact factor: 9.079

9.  U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin.

Authors:  D R Snydman; L A McDermott; N V Jacobus; C Thorpe; S Stone; S G Jenkins; E J C Goldstein; R Patel; B A Forbes; S Mirrett; S Johnson; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

10.  In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii.

Authors:  David M Livermore; Shazad Mushtaq; Marina Warner; Neil Woodford
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191
View more
  4 in total

Review 1.  Antimicrobial Resistance in ESKAPE Pathogens.

Authors:  David M P De Oliveira; Brian M Forde; Timothy J Kidd; Patrick N A Harris; Mark A Schembri; Scott A Beatson; David L Paterson; Mark J Walker
Journal:  Clin Microbiol Rev       Date:  2020-05-13       Impact factor: 26.132

2.  Eravacycline activity against clinical S. aureus isolates from China: in vitro activity, MLST profiles and heteroresistance.

Authors:  Fan Zhang; Bing Bai; Guang-Jian Xu; Zhi-Wei Lin; Gui-Qiu Li; Zhong Chen; Hang Cheng; Xiang Sun; Hong-Yan Wang; Yan-Wei Chen; Jin-Xin Zheng; Qi-Wen Deng; Zhi-Jian Yu
Journal:  BMC Microbiol       Date:  2018-12-13       Impact factor: 3.605

3.  In vitro activity of eravacycline against common ribotypes of Clostridioides difficile.

Authors:  Eugénie Bassères; Khurshida Begum; Chris Lancaster; Anne J Gonzales-Luna; Travis J Carlson; Julie Miranda; Tasnuva Rashid; M Jahangir Alam; David W Eyre; Mark H Wilcox; Kevin W Garey
Journal:  J Antimicrob Chemother       Date:  2020-10-01       Impact factor: 5.790

Review 4.  New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives.

Authors:  Marco Terreni; Marina Taccani; Massimo Pregnolato
Journal:  Molecules       Date:  2021-05-02       Impact factor: 4.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.